Forfivo XL (Bupropion HCl) Patent Expiration, LOE Window & CMS Spending
Forfivo XL (Bupropion HCl) by Twi: FDA Orange Book LOE 2028-08-23, 32 AB generics, $633K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Twi |
| FDA Application & Pathway | N022497 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-08-23 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 32 |
| 2024 CMS Total Public Spend | $633K |
| 2024 Medicare Part D Spend | $237K |
| 2024 Medicaid Spend | $397K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |